Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 15/20 | 0.45 |
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.45 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.45 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.45 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4993614 | 0.89 | EGLN1 (0.44) | EGLN1EGLN3EGLN2OGFOD1HIF1AN | |
| SCHEMBL4737006 | 0.88 | EGLN1 (0.52) | EGLN1EGLN3EGLN2OGFOD1HIF1AN | |
| SCHEMBL5000019 | 0.85 | EGLN1 (0.43) | EGLN1EGLN3EGLN2OGFOD1HIF1AN | |
| SCHEMBL4985569 | 0.85 | EGLN1 (0.44) | EGLN1EGLN3EGLN2OGFOD1HIF1AN | |
| SCHEMBL4992285 | 0.85 | EGLN1 (0.54) | EGLN1EGLN3EGLN2OGFOD1HIF1AN | |
| SCHEMBL4988793 | 0.84 | EGLN3 (0.46) | EGLN1EGLN3EGLN2OGFOD1HIF1AN | |
| SCHEMBL4994439 | 0.84 | EGLN3 (0.44) | EGLN1EGLN3EGLN2OGFOD1HIF1AN | |
| SCHEMBL4991812 | 0.84 | EGLN1 (0.44) | EGLN1EGLN3EGLN2OGFOD1HIF1AN | |
| SCHEMBL4992314 | 0.84 | EGLN1 (0.44) | EGLN1EGLN3EGLN2OGFOD1HIF1AN | |
| SCHEMBL4995450 | 0.83 | EGLN3 (0.43) | EGLN1EGLN3EGLN2OGFOD1HIF1AN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | claimed |
| WO-2008089051-A1 | N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | EGLN1 5/4885EGLN3 3/4885EGLN2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.